Grufity logoGrufity logo
StocksFundsScreenerSectorsWatchlists
SLGC

SLGC - SomaLogic, Inc. Stock Price, Fair Value and News

2.10USD Market Closed
Watchlist

Market Summary

USD2.10
Market Closed

SLGC Alerts

  • ARK Investment Management LLC reported owning 7.55% of SLGC [2024-01-29]

SLGC Stock Price

View Fullscreen

SLGC RSI Chart

SLGC Valuation

Market Cap

395.0M

Price/Earnings (Trailing)

-3.03

Price/Sales (Trailing)

4.83

EV/EBITDA

-0.73

Price/Free Cashflow

-3.26

SLGC Price/Sales (Trailing)

SLGC Profitability

EBT Margin

-159.08%

Return on Equity

-26.25%

Return on Assets

-23.07%

Free Cashflow Yield

-30.69%

SLGC Fundamentals

SLGC Revenue

Revenue (TTM)

81.7M

Rev. Growth (Yr)

-47.14%

Rev. Growth (Qtr)

7.72%

SLGC Earnings

Earnings (TTM)

-130.4M

Earnings Growth (Yr)

32.74%

Earnings Growth (Qtr)

10.56%

Breaking Down SLGC Revenue

Last 7 days

-17%

Last 30 days

-25.8%

Last 90 days

-0.9%

Trailing 12 Months

-16.3%

How does SLGC drawdown profile look like?

SLGC Financial Health

Current Ratio

17.79

SLGC Investor Care

Shares Dilution (1Y)

0.29%

Diluted EPS (TTM)

-0.69

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs
Net sales
YearQ1Q2Q3Q4
202395.1M101.4M81.7M0
202285.7M80.1M101.8M97.7M
202162.3M68.8M75.2M81.6M
202000055.9M

Tracking the Latest Insider Buys and Sells of SomaLogic, Inc.

Filter Transactions
Datesorted ascendingNameBuy/Sell$ ValueAvg. Price# SharesTitle
Jan 05, 2024
post richard a
back to issuer
-
-
-57,430
-
Jan 05, 2024
roelke alison marie
back to issuer
-
-
-17,143
chief people officer
Jan 05, 2024
barchi robert
back to issuer
-
-
-7,630
-
Jan 05, 2024
casdin eli
back to issuer
-
-
-6,800,000
-
Jan 05, 2024
casdin eli
back to issuer
-
-
-2,472,270
-
Jan 05, 2024
gutierrez ruben
back to issuer
-
-
-21,027
general counsel
Jan 05, 2024
casdin eli
back to issuer
-
-
-10,132,000
-
Jan 05, 2024
cox troy
back to issuer
-
-
-78,430
-
Jan 05, 2024
margulies anne h.
back to issuer
-
-
-10,132,000
-
Jan 05, 2024
margulies anne h.
back to issuer
-
-
-2,472,270
-

1–10 of 50

Which funds bought or sold SLGC recently?

View All Details
Datesorted ascendingFund NameType% Chg$ Change$ Held% Portfolio
Feb 16, 2024
PRICE T ROWE ASSOCIATES INC /MD/
unchanged
-
-11,000
14,000
-%
Feb 16, 2024
PRICE T ROWE ASSOCIATES INC /MD/
reduced
-10.08
-10,000
189,000
-%
Feb 15, 2024
GTS SECURITIES LLC
new
-
39,405
39,405
-%
Feb 15, 2024
JANE STREET GROUP, LLC
added
1,175
477,868
516,084
-%
Feb 15, 2024
Legal & General Group Plc
added
6.52
43,844
387,554
-%
Feb 15, 2024
Farther Finance Advisors, LLC
new
-
706
706
-%
Feb 15, 2024
BARCLAYS PLC
added
5.74
741,000
6,947,000
-%
Feb 14, 2024
Mariner, LLC
new
-
65,082
65,082
-%
Feb 14, 2024
BOOTHBAY FUND MANAGEMENT, LLC
reduced
-18.89
-100,308
609,118
0.02%
Feb 14, 2024
PERCEPTIVE ADVISORS LLC
sold off
-100
-3,585,000
-
-%

1–10 of 46

Are Funds Buying or Selling SLGC?

Are funds buying SLGC calls or puts?
Calls
Puts
No. of funds holding Calls - Puts
Net Call Options
No. of funds that own SLGC
No. of Funds

Unveiling SomaLogic, Inc.'s Major ShareHolders

Date FiledName of FilerPercent of ClassNo. of SharesForm Type
Jan 29, 2024
blackrock inc.
6.1%
11,548,774
SC 13G/A
Jan 29, 2024
ark investment management llc
7.55%
14,241,979
SC 13G/A
Jan 09, 2024
cmls holdings ii llc
0%
0
SC 13D/A
Feb 14, 2023
gold lawrence marshall
1.9%
3,627,197
SC 13G/A
Feb 03, 2023
blackrock inc.
5.5%
10,268,281
SC 13G
Dec 14, 2022
cmls holdings ii llc
5.8%
11,146,669
SC 13D/A
Feb 11, 2022
gold lawrence marshall
5.04%
9,133,066
SC 13G

Recent SEC filings of SomaLogic, Inc.

View All Filings
Date Filed Form Type Document
Jan 29, 2024
SC 13G/A
Major Ownership Report
Jan 29, 2024
SC 13G/A
Major Ownership Report
Jan 16, 2024
15-12G
15-12G
Jan 11, 2024
EFFECT
EFFECT
Jan 11, 2024
EFFECT
EFFECT
Jan 09, 2024
4
Insider Trading
Jan 09, 2024
SC 13D/A
13D - Major Acquisition
Jan 09, 2024
4
Insider Trading
Jan 09, 2024
4
Insider Trading
Jan 09, 2024
4
Insider Trading

Peers (Alternatives to SomaLogic, Inc.)

NameMkt Capsorted ascendingRevenuePrice %, 1MReturns, 1YP/EP/SRev 1-YrInc 1-Yr
LARGE-CAP
487.6B
360.0B
0.01% 5.90%
22.49
1.35
14.24% 11.62%
97.1B
357.8B
0.71% -14.01%
11.63
0.27
10.95% 93.52%
83.4B
65.0B
9.34% 20.24%
15.91
1.28
7.86% -7.11%
42.9B
154.0B
-0.09% 8.25%
15.86
0.28
6.54% 124.79%
11.3B
14.0B
2.25% 10.28%
16.73
0.81
6.03% -8.61%
11.0B
12.1B
12.03% 47.11%
15.88
0.9
4.57% 23.40%
MID-CAP
9.0B
2.2B
0.13% 16.69%
36.85
4.05
4.50% -6.69%
7.8B
2.9B
-3.46% 1.96%
-425.45
2.72
13.16% -106.47%
2.1B
3.8B
-19.95% -33.62%
9.84
0.55
-27.73% -52.50%
SMALL-CAP
2.4B
1.3B
4.99% 11.37%
53.3
1.79
27.06% -27.04%
1.4B
1.0B
8.40% -11.51%
25.01
1.4
10.84% 30.19%
994.0M
3.0B
7.30% 124.36%
-5.26
0.33
6.74% 20.73%
42.1M
-
-0.60% -54.62%
-2.91
-
- -27.68%
16.9M
20.7M
- -15.62%
83.48
0.82
6.53% -85.60%

SomaLogic, Inc. News

Latest updates
GlobeNewswire2 months ago

SomaLogic, Inc. Earnings Report: Key Takeaways & Analysis

Income Statement (Last 12 Months)
Income Statement (Quarterly)
Description(%) Q/Q2023Q32023Q22023Q12022Q42022Q32022Q22022Q12021Q42021Q32021Q22021Q12020Q42020Q3
Revenue7.7%22,048,00020,468,00020,379,00018,829,00041,713,00014,144,00022,980,00022,994,00019,992,00019,780,00018,860,00016,546,50014,233,000
Operating Expenses-2.8%50,130,00051,563,00060,572,00073,310,00082,325,00061,525,00056,267,00051,352,00044,998,00031,408,00027,172,000-20,134,000
  S&GA Expenses-19.3%23,880,00029,573,00034,189,00040,038,00049,511,00036,812,00030,815,00029,697,00020,632,00014,833,00012,809,000-8,337,000
  R&D Expenses-3.3%10,458,00010,815,00014,067,00022,589,00019,419,00017,636,00013,800,00011,192,00015,596,0008,590,0008,118,000-6,884,000
EBITDA Margin-12.5%-1.50-1.34-1.42-1.08-0.82-1.06-0.99-1.02-----
Interest Expenses---------2,000148,0001,174,000-1,595,000
Income Taxes23800.0%478,0002,0002,000-116,000-600,0005,0003,000------
Earnings Before Taxes12.5%-21,679,000-24,770,000-34,200,000-49,358,000-33,560,000-22,980,000-3,976,000--41,419,000----
EBT Margin-13.7%-1.59-1.40-1.47-1.12-0.86-1.09-1.02-1.07-----
Net Income10.6%-22,157,000-24,772,000-34,202,000-49,251,000-32,942,000-22,985,000-3,979,000-23,307,000-41,419,000-13,337,000-9,484,000-8,914,000-7,483,000
Net Income Margin-14.6%-1.60-1.39-1.47-1.12-0.82-1.14-0.96-1.07-0.97-0.57-0.72-0.95-
Free Cashflow19.9%-21,736,000-27,123,000-44,307,000-28,053,000-39,417,000-32,135,000-6,279,000-18,224,000-17,880,000-3,504,000-4,083,000--
Balance Sheet
(In Millions)
Balance Sheet
(In Millions)
(*) denotes actual numbers (not divided by Millions)
Description(%) Q/Q2023Q32023Q22023Q12022Q42022Q32022Q22022Q12021Q42021Q32021Q22021Q12020Q4
Assets-3.5%565586614647688686713706719277278242
  Current Assets-4.3%4945165475826216596906927071.002.00232
    Cash Equivalents-13.8%30635543942238041843844046947.0085.00165
  Inventory-8.2%14.0015.0015.0014.0018.0021.0014.0011.0011.00--7.00
  Net PPE-2.7%18.0019.0020.0020.0020.0016.0012.0010.006.00--4.00
  Goodwill0%10.0010.0010.0010.0010.00-------
Liabilities-3.2%68.0071.0079.0085.0086.0079.0096.0094.0093.0068.0052.0056.00
  Current Liabilities-11.8%28.0032.0039.0043.0043.0035.0028.0029.0022.000.000.0018.00
Shareholder's Equity-3.6%497515535563603607617612626174181186
  Retained Earnings-3.3%-689-667-642-608-558-525-502-498-475-43.28-26.41-411
  Additional Paid-In Capital0.3%1,1861,1831,1781,1711,1621,1341,1211,1111,10148.0031.00597
Accumulated Depreciation8.1%23.0021.0020.0018.0017.0016.0016.0015.00----
Shares Outstanding0.3%189188188188183183182182137115114114
Cashflow (Last 12 Months)
(In Thousands)
Cashflow (Quarterly)
(In Thousands)
(*) denotes actual numbers (not divided by Thousands)
Description(%) Q/Q2023Q32023Q22023Q12022Q42022Q32022Q22022Q12021Q42021Q32021Q22021Q12020Q42020Q3
Cashflow From Operations18.6%-21,365-26,237-43,045-26,608-37,785-30,361-5,915-17,938-15,821-2,734-3,891--
  Share Based Compensation-7.0%4,0044,3077,1838,58416,8949,4608,6717,71512,6844,7643,252--
Cashflow From Investing52.4%-27,579-57,97255,27967,8055126,8587,367-11,682-98,1493,494-75,682--
Cashflow From Financing-100.0%-250172300-3,6431,242403535,548-39,077617--

SLGC Income Statement

2023-09-30
Condensed Consolidated Statements of Operations and Comprehensive Loss - USD ($)
$ in Thousands
3 Months Ended9 Months Ended
Sep. 30, 2023
Sep. 30, 2022
Sep. 30, 2023
Sep. 30, 2022
Revenue    
Collaboration revenue$ 763$ 763$ 2,288$ 2,288
Total revenue22,04841,71362,89578,837
Operating expenses    
Research and development10,45819,41935,34050,855
Selling, general and administrative23,88049,51187,642116,024
Transaction costs4,1571,7254,1572,839
Total operating expenses50,13082,325162,265200,117
Loss from operations(28,082)(40,612)(99,370)(121,280)
Other income    
Interest income and other, net6,0872,42116,8103,468
Change in fair value of warrant liabilities3163,3711,89630,547
Change in fair value of earn-out liability01,2601526,749
Total other income6,4037,05218,72160,764
Net loss before income tax (provision) benefit(21,679)(33,560)(80,649)(60,516)
Income tax (provision) benefit(478)618(482)610
Net loss(22,157)(32,942)(81,131)(59,906)
Other comprehensive income (loss)    
Net unrealized (loss) gain on available-for-sale securities(27)(13)501(874)
Foreign currency translation loss(4)(14)(2)(28)
Total other comprehensive (loss) income(31)(27)499(902)
Comprehensive loss$ (22,188)$ (32,969)$ (80,632)$ (60,808)
Net loss per share, basic (in usd per share)$ (0.12)$ (0.18)$ (0.43)$ (0.33)
Net loss per share, diluted (in usd per share)$ (0.12)$ (0.18)$ (0.43)$ (0.33)
Weighted-average shares outstanding used to compute net loss per share, basic (in shares)187,070,510184,407,874186,780,699183,209,213
Weighted-average shares outstanding used to compute net loss per share, diluted (in shares)187,070,510184,407,874186,780,699183,209,213
Assay services revenue    
Revenue    
Revenue$ 17,866$ 17,574$ 52,882$ 47,305
Operating expenses    
Cost of revenue9,99411,26431,35329,215
Product revenue    
Revenue    
Revenue3,4181,0517,5132,218
Operating expenses    
Cost of revenue1,6414063,7731,184
Other revenue    
Revenue    
Revenue$ 1$ 22,325$ 212$ 27,026

SLGC Balance Sheet

2023-09-30
Condensed Consolidated Balance Sheets - USD ($)
$ in Thousands
Sep. 30, 2023
Dec. 31, 2022
Current assets  
Cash and cash equivalents$ 305,571$ 421,830
Investments148,239117,758
Accounts receivable, net20,73017,006
Inventory13,88413,897
Deferred costs of services3791,337
Prepaid expenses and other current assets5,3029,873
Total current assets494,105581,701
Non-current inventory11,1194,643
Accounts receivable, net of current portion8,6819,284
Property and equipment, net of accumulated depreciation and amortization of $23,126 and $17,899 as of September 30, 2023 and December 31, 2022, respectively18,17219,564
Other long-term assets5,8725,083
Intangible assets16,70016,700
Goodwill10,39910,399
Total assets565,048647,374
Current liabilities  
Accounts payable11,45816,794
Accrued liabilities10,82920,678
Deferred revenue3,0743,383
Other current liabilities2,4202,477
Total current liabilities27,78143,332
Warrant liabilities2,3174,213
Deferred revenue, net of current portion30,94431,732
Other long-term liabilities7,2675,539
Total liabilities68,30984,816
Commitments and contingencies (Note 10)
Stockholders’ equity  
Preferred stock, $0.0001 par value; 1,000,000 shares authorized; no shares issued and outstanding at September 30, 2023 and December 31, 202200
Common stock, $0.0001 par value; 600,000,000 shares authorized; 188,662,349 and 187,647,973 shares issued and outstanding at September 30, 2023 and December 31, 2022, respectively1919
Additional paid-in capital1,186,4201,171,122
Accumulated other comprehensive income (loss)(14)(513)
Accumulated deficit(689,686)(608,070)
Total stockholders’ equity496,739562,558
Total liabilities and stockholders’ equity$ 565,048$ 647,374
SLGC
SomaLogic, Inc. operates as a protein biomarker discovery and clinical diagnostics company in the United States. It develops slow off-rate modified aptamers (SOMAmers), which are modified nucleic acid-based protein binding reagents that are specific for its cognate protein; and offers proprietary SomaScan services, which provide multiplex protein detection and quantification of protein levels in complex biological samples. The company's SOMAmers/SomaScan technology enables researchers to analyze various biological samples for protein biomarker signatures, which are utilized in drug discovery and development. Its SomaScan's biomarker discoveries use in diagnostic applications for various diseases, including cardiovascular and metabolic disease, nonalcoholic steatohepatitis, wellness, and others. The company also provides SomaSignal, a laboratory-developed test. It serves pharmaceutical and biotechnology companies, and academic and government research institutions. The company has a collaboration agreement with Illumina Cambridge, Ltd for the development of co-branded NGS-based proteomic distributable kits. The company was founded in 1999 and is headquartered in Boulder, Colorado.
 CEO
 WEBSITEwww.somalogic.com
 EMPLOYEES451

SomaLogic, Inc. Frequently Asked Questions


What is the ticker symbol for SomaLogic, Inc.? What does SLGC stand for in stocks?

SLGC is the stock ticker symbol of SomaLogic, Inc.. Every public company that trades on a stock exchange gets a ticker symbol.

What is the market capital of SomaLogic, Inc. (SLGC)?

As of Fri Jan 05 2024, market cap of SomaLogic, Inc. is 394.95 Million. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

What is the fair value of SLGC stock?

You can check SLGC's fair value in chart for subscribers.

What is the fair value of SLGC stock?

You can check SLGC's fair value in chart for subscribers. The fair value of SomaLogic, Inc. is provided for various growth and macro-economic scenarios from very pessimiatic to very optimistic assumptions. These fair values are estimates from Grufity's Fair Value model based on company's past performance. However, past performance of SomaLogic, Inc. is no guarantee of future performance. These fairvalue estimates should only be used as one of the inputs in your stock analysis. We provide model's historical fair value estimates for SLGC so that you know how good or bad the model has been in the past so you can discard it if needed. There are others that provide fair values of stocks such as wallmine, finbox, gurufocus and finviz. Most provide point in time estimates. We provide a history of our models fair value estimates so that you can get a sense of it's usefulness. Otherwise this data point is of little use.

Is SomaLogic, Inc. a good stock to buy?

The fair value guage provides a quick view whether SLGC is over valued or under valued. Whether SomaLogic, Inc. is cheap or expensive depends on the assumptions which impact SomaLogic, Inc.'s fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for SLGC.

What is SomaLogic, Inc.'s Price to Earnings (PE) and Price to sales (PS) ratio?

As of Fri Jan 05 2024, SLGC's PE ratio (Price to Earnings) is -3.03 and Price to Sales (PS) ratio is 4.83. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. SLGC PE ratio will change depending on the future growth rate expectations of investors.